Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch(Universitätszahnklinik Wien), Matthias Preusser(Medical University of Vienna), Thorsten Fuereder(Medical University of Vienna), Sophie Roider‐Schur, Leopold Oehler, Birgit Gruenberger(Fachhochschule Wiener Neustadt), Rainer Puhr(Medical University of Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Anna S. Berghoff(Medical University of Vienna), Heidrun Forstner(Medical University of Vienna), Julia Furtner(Medical University of Vienna), Christoph Minichsdorfer(Medical University of Vienna), Angelika M. Starzer(Medical University of Vienna), Elisabeth Bergen(Medical University of Vienna), Karin Dieckmann(University of Vienna), Maximilian Marhold(Medical University of Vienna), Georg Widhalm(Medical University of Vienna), Helmuth Haslacher(Medical University of Vienna), Beate Rottenmanner(Medical University of Vienna), Thomas Szekeres(Medical University of Vienna), Ansgar Weltermann, Aysegül Ilhan‐Mutlu(Medical University of Vienna)
Nature Medicine
August 8, 2022
Cited by 395


Related Papers